Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... , , 1. Visit ... Visit your local doctor one month prior to your intended trip departure date. ... , , ... , Discuss with your doctor or a Travellers ...
... JERUSALEM , June 2, 2010 ... systems, announced,today that its subsidiary Oramed Ltd. entered into a ... Israeli company listed on,the Tel Aviv Stock Exchange, for the ... ("Entera"). Under the terms of the agreement, Oramed,will out-license technology ...
Cached Medicine Technology:Medical Tips for Traveling to the 2010 World Cup from WorldNomads.com 2Medical Tips for Traveling to the 2010 World Cup from WorldNomads.com 3Medical Tips for Traveling to the 2010 World Cup from WorldNomads.com 4Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... length may be showing a genetic propensity for obesity as ... have been linked to increased body fat, but the same ... muscle, the researchers said. At 1 year, kids with ... and 3, however, these genes were linked to excessive weight ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... , TUESDAY, Nov. 30 (HealthDay News) -- Autistic children are ... called the mitochondria, which is responsible for producing the energy ... may help to explain the onset or the severity of ... Dec. 1 issue of the Journal of the American ...
... Workers with chronic low back pain can be treated for ... instead of traditional medical care, a new study suggests. ... countries, with 93 percent of the losses having to do ... the Netherlands tested a new approach among 134 patients, aged ...
... Academy of Otolaryngology Head and Neck Surgery (AAO-HNS), ... surgeons, has partnered with SAGE to publish its official ... in January 2011. A leading journal in the ... recent developments in treatment of the ear, nose, throat, ...
... presented today at the annual meeting of the Radiological Society ... in the body of a human drug courier, known as ... from South America is making its way to Europe through ... of Berne and Institute of Forensic Medicine of Berne in ...
... mammogram greatly reduces the risk of mastectomy following breast cancer ... to a study presented today at the annual meeting of ... of this study support the importance of regular screening in ... M. Perry, M.B.B.S., F.R.C.S., F.R.C.R., director of The London Breast ...
... over-the-counter (OTC) medicines for children in the United States are ... to a study in the December 1 issue of ... of inconsistency in labels and measuring devices of OTC liquid ... of pediatrics at NYU School of Medicine who co-led the ...
Cached Medicine News:Health News:Cell Dysfunction May Play Part in Autism 2Health News:Cell Dysfunction May Play Part in Autism 3Health News:Workers With Low Back Pain Benefit From Integrated Care 2Health News:AAO-HNSF partners with SAGE to publish Otolaryngology-Head and Neck Surgery 2Health News:CT best at uncovering drug mule payload 2Health News:Annual breast cancer screening beginning at age 40 reduces mastectomy risk 2Health News:Instructions on over-the-counter medications for children are found to be confusing 2
... unique microprocessor controlled shaking incubator that accommodates ... or 384 well format. Speed, temperature and ... and all are displayed on the LCD. ... protective cover. The Millennium 2000 can be ...
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
... FACSCalibur is the only four-color, automated ... both analysis and cell sorting. Designed specifically ... the FACSCalibur system offers software instrument control, ... maximum ease and productivity. FACSCalibur is fully ...
Multiparameter laser and arc lamp flow cytometer for all applications in immunology, microbiology, cell biology, pathology, hematology, lymphocyte dubset and cell analysis....
Medicine Products: